All In MedTech

Device Trial Radar · NCT05549453

Use of Nexstim SNBT System

Use of Nexstim SNBT System in Its Intended Use

Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Sep 26, 2022

Primary completion

Dec 31, 2022

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Nexstim LtdNot on our public-company list
Sponsor type
Industry
First posted
Sep 22, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The clinical investigation assesses the usability of the new graphical user interface of the Nexstim SNBT device in its intended clinical uses. The hardware and the technical functionality of the device of the SNBT device are in other respects similar to those of the earlier Nexstim NBT device, which has been cleared by FDA for treatment of Major Depressive Disorder in 2017 (K170902) and has received EU CE mark for the same and for treatment of chronic neuropathic pain. The present investigation is not intended to establish the safety and efficacy of the SNBT device. Rather, the purpose is to assess the usability of the new user interface in a feasibility study conducted with a prototype device utilizing the new user interface.

Conditions

  • Usability of the Graphical User Interface of the Device for Its Intended Use

Interventions

  • Nexstim SNBT useDevice

    Active device use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of usability of the graphical user interface for use of the device in its intended useTime frame: Up to 3 months. From subject's enrollment to end of subject's study participation.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nexstim Plc

    Helsinki, Uusimaa, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.